The following is a listing of myeloma treatments associated with this tag.
View all treatments in development for myeloma patients around the US.
CAR2 Anti-CD38 A2 CAR-T Cells
CAR2 Anti-CD38 A2 CAR-T Cells have the key advantage of selectively killing high expressing CD38 positive cells, which are mostly cancer cells and thus, may limit on-target/off-tumor toxicity.
Descartes-08
Descartes-08 is a cell therapy wherein T-cells are modified to attack myeloma cells. To modify the cells, new instructions (called RNA) are inserted into the T-cells.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.
Descartes-08
Descartes-08 is a cell therapy wherein T-cells are modified to attack myeloma cells. To modify the cells, new instructions (called RNA) are inserted into the T-cells.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.
CAR2 Anti-CD38 A2 CAR-T Cells
CAR2 Anti-CD38 A2 CAR-T Cells have the key advantage of selectively killing high expressing CD38 positive cells, which are mostly cancer cells and thus, may limit on-target/off-tumor toxicity.
Descartes-08
Descartes-08 is a cell therapy wherein T-cells are modified to attack myeloma cells. To modify the cells, new instructions (called RNA) are inserted into the T-cells.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of myeloma clinical trials associated with this tag.
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
The following is a listing of myeloma centers associated with this tag.
SparkCures Verified Accurate, up-to-date information. Learn more
Mayo Clinic (Scottsdale)
Scottsdale, AZ
Moores Cancer Center UC San Diego Health
La Jolla, CA
University of California San Francisco UCSF Medical Center at Parnassus
San Francisco, CA
University of Kansas Cancer Center
Kansas City, KS
Dana-Farber Cancer Institute
Boston, MA
Massachusetts General Hospital
Boston, MA
Beth Israel Deaconess Medical Center
Boston, MA
National Institutes of Health (NIH)
Bethesda, MD
Levine Cancer Institute Atrium Health
Charlotte, NC
Roswell Park Cancer Institute
Buffalo, NY
Mount Sinai Hospital Tisch Cancer Institute
New York, NY
Abramson Cancer Center University of Pennsylvania
Philadelphia, PA
Roger Williams Medical Center
Providence, RI
Sarah Cannon TriStar Centennial Medical Center
Nashville, TN
Swedish Cancer Institute Cherry Hill Campus
Seattle, WA
The following is a listing of myeloma tags that are associated with this tag.
B-Cell Maturation Antigen (BCMA)
B-Cell Maturation Antigen (BCMA) is a protein that may be found on the surface of myeloma cells. BCMA may be used as a target to help treatments find and destroy myeloma cells.
CD38
CD38 is a protein that may be found on the surface of many immune system cells (including multiple myeloma cells). This protein may be used as a way for treatments to target (or find) myeloma cells.